Targanta Raising $50 Million

Targanta Therapeutics Inc. (f.k.a. PhageTech), a Cambridge, Mass.-based developer of antibacterial agents, is nearing a $50 million Series C deal, according to comments made by company CEO Mark Leuchtenberger during this week's J.P. Morgan Healthcare Conference. http://www.targanta.com/